Search results for "FDA update"
First NASH treatment, over-the-counter CGM approved
This column reviews recent recalls, alerts, and approvals.
https://immattersacp.org/archives/2024/05/first-nash-treatment-over-the-counter-cgm-approved.htm
1 May 2024
Asthma drugs get risk management program
And the winner is …
https://immattersacp.org/weekly/archives/2010/03/02/9.htm
2 Mar 2010
CPAP masks with magnets recalled
This column reviews recent recalls, alerts, and approvals.
https://immattersacp.org/archives/2024/03/cpap-masks-with-magnets-recalled.htm
1 Mar 2024
Hemodialysis system recalled
The Aquarius Hemodialysis System is being recalled due to reports of clinically significant fluid imbalance and the potential for users to repeatedly override the fluid imbalance alarm, the FDA announced last week.
https://immattersacp.org/weekly/archives/2010/02/09/8.htm
9 Feb 2010
First medication for severe frostbite approved
This column reviews recent recalls, alerts, and approvals.
https://immattersacp.org/archives/2024/04/first-medication-for-severe-frostbite-approved.htm
1 Apr 2024
Rosuvastatin approved for patients without heart disease
ICD-10 summit to be held in April
https://immattersacp.org/weekly/archives/2010/02/16/7.htm
16 Feb 2010
Warning on steroids; approval for soft-tissue sarcoma drug
This column reviews a warning on testosterone and other anabolic androgenic steroids and approval of a new drug to treat certain adults with soft-tissue sarcoma.
https://immattersacp.org/archives/2017/01/fda-update.htm
1 Jan 2017
Valproate contraindicated for migraines in pregnant women
Valproate sodium and related products, valproic acid and divalproex sodium, are now contraindicated for prevention of migraine headaches in pregnant women, the FDA announced last week.
https://immattersacp.org/weekly/archives/2013/05/14/6.htm
14 May 2013
Warnings about topical antiseptics, nuclear stress test agents
This regulatory update covers label and packaging changes to over-the-counter topical antiseptic products due to infection risk and approval of the first generic versions of rabeprazole sodium for gastroesophageal reflux disease.
https://immattersacp.org/archives/2014/02/fda.htm
1 Feb 2014
New limitations on tolvaptan due to liver injury risk
The labeling for tolvaptan (Samsca) has been revised due to observation of increased risk of liver injury in recent trials, the FDA announced last week.
https://immattersacp.org/weekly/archives/2013/05/07/7.htm
7 May 2013